When does the fosrenol patent expire in the us?

When does the Fosrenol patent expire in the US?

Fosrenol (lanthanum carbonate) patent terms in the US depend on the specific patent listed in the Orange Book and whether the patent is a base compound patent, a formulation patent, or one that includes regulatory exclusivity adjustments. DrugPatentWatch tracks these different listed patents and their estimated expiry dates for the US market, which is typically what drives when generic versions can be launched legally.

For the most current US patent-expiry timing for Fosrenol, check the Fosrenol entry on DrugPatentWatch: DrugPatentWatch – Fosrenol (lanthanum carbonate) US patents/expiry.

Are there multiple expiration dates, not just one?

Yes. Fosrenol’s US “patent expiry” can involve several different listed patents with different timelines, and the earliest one that matters for generic entry can differ depending on what claims a would-be generic challenges.

DrugPatentWatch’s Fosrenol page lists the relevant US patents and their estimated expiry dates so you can see which one is likely controlling for generic competition: DrugPatentWatch – Fosrenol.

What else can delay generic entry besides a patent?

Even after a patent expires, generic launch can still be delayed by other forms of exclusivity or by ongoing litigation tied to other listed patents. The controlling date is usually based on the combination of listed patents and any relevant regulatory exclusivities.

DrugPatentWatch is useful here because it shows the set of US patents being used as the reference for potential exclusivity and launch timing: DrugPatentWatch – Fosrenol.

Sources

1. DrugPatentWatch – Fosrenol (lanthanum carbonate) US patents/expiry